Prostate cancer, version 1.2021: Prostate Cancer, Version 1.2021

Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D'Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George NettoDavid F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, Deborah A. Freedman-Cass

Research output: Contribution to journalArticlepeer-review

315 Scopus citations

Abstract

The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease. Recommendations for disease monitoring and treatment of recurrent disease are also included. The NCCN Prostate Cancer Panel meets annually to reevaluate and update their recommendations based on new clinical data and input from within NCCN Member Institutions and from external entities. This article summarizes the panel's discussions for the 2021 update of the guidelines with regard to systemic therapy for metastatic castration-resistant prostate cancer.

Original languageEnglish
Pages (from-to)134-143
Number of pages10
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume19
Issue number2
DOIs
StatePublished - Feb 2 2021

Keywords

  • Humans
  • Male
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Prostatic Neoplasms, Castration-Resistant
  • Prostatic Neoplasms/diagnosis
  • Risk Assessment

Fingerprint

Dive into the research topics of 'Prostate cancer, version 1.2021: Prostate Cancer, Version 1.2021'. Together they form a unique fingerprint.

Cite this